Valuation: Swedish Orphan Biovitrum AB

Capitalization 137B 15.19B 12.84B 11.77B 11.14B 20.76B 1,375B 21.63B 54.1B 661B 56.95B 55.77B 2,405B P/E ratio 2025
243x
P/E ratio 2026 * 23.1x
Enterprise value 147B 16.37B 13.84B 12.68B 12.01B 22.38B 1,482B 23.31B 58.32B 713B 61.39B 60.13B 2,593B EV / Sales 2025
4.06x
EV / Sales 2026 * 4.59x
Free-Float
51.66%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+2.27%
1 week+17.45%
Current month+17.45%
1 month+17.24%
3 months+21.41%
6 months+44.45%
Current year+18.93%
More quotes
1 week 335.6
Extreme 335.6
395.8
1 month 322
Extreme 322
395.8
Current year 322
Extreme 322
395.8
1 year 241.8
Extreme 241.8
395.8
3 years 197.9
Extreme 197.9
395.8
5 years 127.1
Extreme 127.1
395.8
10 years 89.5
Extreme 89.5
395.8
More quotes
Manager TitleAgeSince
Chief Executive Officer 61 22/05/2017
Director of Finance/CFO 59 20/07/2018
Chief Tech/Sci/R&D Officer 55 -
Director TitleAgeSince
Director/Board Member 57 01/01/2020
Director/Board Member 70 01/01/2021
Director/Board Member - -
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+2.27%+17.45%+23.30%+67.93% 15.17B
+2.46%+5.94%+10.64%+2.02% 80.61B
-0.41%-0.51%-33.11%-41.41% 61B
-2.31%+2.58%+38.44%+244.10% 58.81B
-1.88%+66.80%+66.80%+66.80% 52.77B
+8.53%+11.84%+42.33%-30.97% 29.52B
+5.48%+8.31%+46.22%+33.88% 21.28B
-0.50%-1.97%+119.31%+84.45% 17.65B
+0.34%-6.94%+25.80%-76.03% 16.02B
-0.04%-.--%+3.83%+178.97% 14.02B
Average +1.39%+2.75%+34.35%+52.98% 36.69B
Weighted average by Cap. +0.92%+2.65%+26.67%+52.16%
See all sector performances

Financials

2025 2026 *
Net sales 28.43B 3.16B 2.67B 2.44B 2.32B 4.31B 286B 4.49B 11.24B 137B 11.83B 11.59B 500B 31.33B 3.48B 2.94B 2.69B 2.55B 4.75B 315B 4.95B 12.39B 151B 13.04B 12.77B 551B
Net income 633M 70.23M 59.37M 54.42M 51.53M 96M 6.36B 100M 250M 3.06B 263M 258M 11.12B 5.83B 647M 547M 502M 475M 885M 58.61B 922M 2.31B 28.17B 2.43B 2.38B 102B
Net Debt 10.68B 1.19B 1B 918M 870M 1.62B 107B 1.69B 4.22B 51.6B 4.45B 4.35B 188B 7.1B 788M 666M 610M 578M 1.08B 71.34B 1.12B 2.81B 34.29B 2.95B 2.89B 125B
More financial data * Estimated data
Logo Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Employees
1,888
More about the company
Date Price Change Volume
06/02/26 395.80 kr +2.27% 701,230
05/02/26 387.00 kr +7.98% 1,235,238
04/02/26 358.40 kr +0.45% 465,195
03/02/26 356.80 kr +3.24% 505,076
02/02/26 345.60 kr +2.55% 220,049

Delayed Quote Nasdaq Stockholm, February 06, 2026 at 08:00 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
395.80SEK
Average target price
389.64SEK
Spread / Average Target
-1.56%
Consensus

Quarterly revenue - Rate of surprise